Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22150019 | 0.94 | SLC6A2 (0.31) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25964698 | 0.80 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4755323 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL5766354 | 0.65 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5767479 | 0.65 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5766357 | 0.65 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20713282 | 0.64 | HTR2C (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21949114 | 0.64 | — | — | |
| SCHEMBL24726013 | 0.62 | — | — | |
| SCHEMBL3063847 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365191-B2 | Substituted cyclohexyl compounds as NOP inhibiiors | DART NEUROSCIENCE, LLC (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210340127-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE, LLC | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340127-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | OPRL1, OPRK1, NOP56 | SLC6A2 234/4885SLC6A4 239/4885SLC6A3 168/4885 |
| US-11365191-B2 | Substituted cyclohexyl compounds as NOP inhibiiors | OPRL1, OPRK1, GAP43 | SLC6A2 176/4885SLC6A4 172/4885SLC6A3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.